Framycetin, Inhibitor

Framycetin

Cat. Num. AAA5754878

• Purity: 98.00%
• Synonyms: Framycetin; Fradiomycin B; Neomycin B; inhibitor

• Purity/Purification: 98.00%
• Form/Format: Solid. Powder

• Solubility: H2O: 100mg/mL (162.70mM) Need ultrasonic; DMSO: 50mg/mL (81.35mM) Need ultrasonic; (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: C23H46N6O13
• SMILES: N[C@@H](C[C@H]1N)[C@@]([C@@H]([C@H]1O)O[C@@](O[C@H](CO)[C@H]2O[C@@]([C@@H]([C@@H](O)[C@@H]3O)N)([H])O[C@H]3CN)([H])[C@@H]2O)([H])O[C@H]([C@@H]([C@@H](O)[C@@H]4O)N)O[C@@H]4CN
• CAS Number: 119-04-0
• Target & IC50: hammerhead ribozyme: ic50 13.5uM (ki)
• In Vitro: Neomycin B targets the bacterial and human ribosomes and affects translation. Neomycin B is used clinically to treat hepatic encephalopathy (by reducing ammonium levels in the gut) and enteropathogenic Escherichia coli infections. The addition of neomycin B, to an HCC cell line, selectively inhibits the production of the mature miRNA, boosts a downstream protein, and inhibits invasion [2]. The aminoglycoside antibiotic neomycin B causes misreading of the genetic code during translation and inhibits several ribozymes. The ribosomal target site of neomycin B is the 16 S rRNA 1400 to 1500 region, which has been clearly demonstrated by dissecting this domain from a small RNA of 27 nucleotides. This small subdomain of the 16 S rRNA is protected from chemical modification by neomycin at the same positions as in the context of the 30 S subunit [4]. Neomycin B interacts with various target RNAs that have no primary sequence homology. This means that the drug binds to a structural rather than a sequence motif of the RNA. Its primary cognate target is the decoding site of the 16S rRNA, but it also binds to the Rev-responsive element in HIV-1, a group I introns, and the hammerhead ribozyme, and thus inhibits their biological function [3].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Structure

Related Product Information for Framycetin, inhibitor

Framycetin is an aminoglycoside antibiotic and it also inhibits hammerhead ribozyme (Ki: 13.5uM).

References

Stage TK, et al. Inhibition of the hammerhead ribozyme by neomycin. RNA. 1995 Mar;1(1):95-101.
Stage TK, et al. Inhibition of the hammerhead ribozyme by neomycin. RNA. 1995 Mar;1(1):95-101.
Childs-Disney JL, et al. Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma. ACS Chem Biol. 2016 Feb 19;11(2):375-80.
Childs-Disney JL, et al. Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma. ACS Chem Biol. 2016 Feb 19;11(2):375-80.
Stampfl S, et al. Monovalent ion dependence of neomycin B binding to an RNA aptamer characterized by spectroscopic methods. Chembiochem. 2007 Jul 9;8(10):1137-45.
Stampfl S, et al. Monovalent ion dependence of neomycin B binding to an RNA aptamer characterized by spectroscopic methods. Chembiochem. 2007 Jul 9;8(10):1137-45.
Hoch I, et al. Antibiotic inhibition of RNA catalysis: neomycin B binds to the catalytic core of the td group I intron displacing essential metal ions. J Mol Biol. 1998 Sep 25;282(3):557-69.
Hoch I, et al. Antibiotic inhibition of RNA catalysis: neomycin B binds to the catalytic core of the td group I intron displacing essential metal ions. J Mol Biol. 1998 Sep 25;282(3):557-69.